Pittsburgh-based Highmark Health signed an outcomes-based contract with drugmaker AstraZeneca for its asthma and chronic obstructive pulmonary disease drug Symbicort.
The contract will apply to Highmark's commercial insurance members in national and Pennsylvania, West Virginia and Delaware markets. Highmark said the contract marks one of the first outcomes-based agreements for a drug treating the chronic lung diseases.
Under the contract, if Highmark members who use Symbicort don't have aligned results with clinical trials performed by AstraZeneca, the drugmaker will issue Highmark a rebate.